Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)
| Docket | ⤷ Try a Trial | Date Filed | 2023-02-10 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Jennifer L. Hall |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 10,071,977; 10,149,829; 8,785,492; RE46,604 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-02-10 | 53 | Opinion | , 2018) (adding U.S. Patent No. 10,071,977); see Def. Br. at 5 (noting 15 patents asserted in total). …5. Vanda holds multiple patents relating to tasimelteon. The suit for patent infringement underlying …motion to transfer concerns U.S. Patent No. 11,285,129 (the ’129 patent), which issued on March 29, 2022…related patents. 2 See Compl. ¶¶ 22-39, Vanda Pharms. 2 Vanda originally asserted six patents but added…later-issued patents to the Delaware litigation, Vanda would not assert any additional patents against Teva | External link to document |
| 2023-04-14 | 86 | Brief - Opening Brief in Support | the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious as a …Litigation Involving Related Patents Before asserting the ’129 patent here, Vanda previously sued…the ’829 patent”), both of which are related to the ’129 patent and share a common specification. Following…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. See Vanda Pharm | External link to document |
| 2023-05-12 | 94 | Complaint - Amended | of U.S. Patent No. RE46,604 (“the RE604 patent”) and claim 14 of U.S. Patent No. 10,149,829 (“the ’829…’129 patent was not asserted in the prior litigation, the patentable weight and/or patentability of the…’129 patent was not asserted in the prior litigation, the patentable weight and/or patentability of other…Complaint for infringement of U.S. Patent No. 11,285,129 (the ’129 patent) against Defendant Teva Pharmaceuticals… THE PATENT-IN-SUIT The ’129 Patent 11. | External link to document |
| 2023-06-28 | 99 | Brief - Opening Brief in Support | the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious based…“the ’829 patent”), which are related to the ’129 patent and share a specification. Following a four-…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. Vanda Pharm…between the claims of the ’129 patent and those of the RE604 and ’829 patents is a requirement to determine | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
